Department of Clinical and Developmental Neuropsychology, University of Groningen, Groningen, The Netherlands.
Department of Psychiatry and Psychotherapy, University Medical Center Rostock, Rostock, Germany.
PLoS One. 2020 Sep 18;15(9):e0239257. doi: 10.1371/journal.pone.0239257. eCollection 2020.
This comprehensive review examined sex differences in prescription rates and efficacy or effectiveness of pharmacotherapy treatment in girls and women with attention deficit hyperactivity disorder (ADHD), while identifying gaps in the scientific knowledge on this topic.
A rigorous electronic database search was carried out in order to identify all published studies on female-specific effects of stimulants and non-stimulants in the treatment of ADHD. In total, 2672 studies were screened of which 21 studies (seven on prescription rates, 14 on effects of pharmacotherapy) met the inclusion criteria and were included for analysis.
In all seven studies on ADHD prescription rates, girls received significantly less prescriptions than boys, a difference however no longer seen in adults with the exception of one study. Each of the 14 studies on effectiveness / efficacy found at least one sex-difference in the effects of ADHD pharmacotherapy.
Several sex-differences are demonstrated in the prescription, usage and efficacy /effectiveness of both stimulant and non-stimulant ADHD pharmacotherapy. A single daily use of MPH may possibly not be optimal for girls with ADHD and ATX may be a promising medication for girls and women with ADHD. The robustness of this result requires further investigation.
本综述全面考察了性别差异对注意缺陷多动障碍(ADHD)女童和妇女药物治疗处方率和疗效或有效性的影响,同时确定了该主题科学知识中的空白。
为了确定关于兴奋剂和非兴奋剂在治疗 ADHD 方面对女性的具体影响的所有已发表的研究,我们进行了严格的电子数据库搜索。总共筛选了 2672 项研究,其中有 21 项研究(7 项关于处方率,14 项关于药物治疗效果)符合纳入标准并被纳入分析。
在所有关于 ADHD 处方率的 7 项研究中,女孩的处方量明显少于男孩,但除了一项研究外,这一差异在成年人中不再存在。在关于 ADHD 药物治疗效果的 14 项研究中,每一项都至少发现了一种性别差异。
在兴奋剂和非兴奋剂 ADHD 药物治疗的处方、使用和疗效/效果方面,存在多种性别差异。对于患有 ADHD 的女孩来说,每天使用一次 MPH 可能不是最佳选择,而 ATX 可能是患有 ADHD 的女孩和妇女的一种有前途的药物。这一结果的可靠性需要进一步调查。